A Study to Test the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis

Фаза 3 Завершено NCT03895203

Заболевание	Psoriatic Arthritis
Фаза	Фаза 3
Спонсор	UCB Biopharma SRL
Статус	Завершено
Участники	852 участн.
Вмешательство	Bimekizumab, Adalimumab
Дата начала	3.04.2019
Дата завершения	17.08.2021
Публикация результатов	23.10.2024

Кратко

This is a study to demonstrate the clinical efficacy, safety and tolerability of bimekizumab administered subcutaneously (sc) compared with placebo in the treatment of subjects with active Psoriatic Arthritis (PsA).

Percentage of Participants With an American College of Rheumatology (ACR) 50 Response at Week 16

Week 16 · percentage of participants

Placebo	10.0 percentage of participants
BKZ 160 mg Q4W	43.9 percentage of participants
ADA 40 mg Q2W	45.7 percentage of participants

p-value	<0.001
Odds Ratio (OR)	7.082 (95% CI 4.583–10.943)

Открыть в BENITIONS Открыть на ClinicalTrials.gov

Другие исследования по этому заболеванию

A Study to Assess the Pharmacokinetics, Safety, and Efficacy of Two Doses of Bimekizumab i — UCB Biopharma SRL
A Study of JNJ-77242113 for the Treatment of Participants With Generalized Pustular Psoria — Janssen Pharmaceutical K.K.
A Study of Guselkumab and Golimumab Combination Therapy in Participants With Active Psoria — Janssen Research & Development, LLC
A Study to Evaluate the Efficacy and Safety of Bimekizumab in the Treatment of Subjects Wi — UCB Biopharma SRL
The Efficacy and Safety of TLL018 in Moderate-to-severe Plaque Psoriasis — Hangzhou Highlightll Pharmaceutical Co., Ltd
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis — AbbVie

Все исследования

Страница обобщает открытые данные ClinicalTrials.gov. Это не медицинская и не инвестиционная рекомендация. Обратитесь к врачу.

English 한국어 日本語中文 Русский